Good join begin President of taking Business and by Jeannie. Atkinson, our I'd thank and you, Also everyone, on the today commenting Jim call for our call to commercial and like going towards the like we us. opportunity today. the our to our business us incredible clinical improvements, of Officer. you afternoon, is greater Thank scope to today's Chief time this manufacturing state the have of for address forward. what ahead the business operational means commercial efficiency underscore our on growth, moves I'd and and programs
further which health your today, device leader has first always us development for treatment we'll of the always progress to urinary open through put markets, of United reach taken FDA the the commercial in last Each and our expanded are approvals sexual it have August, been early milestones, the throughout of especially any by incontinence stress towards energy-based in clinical major then potential 'XX, year. made women's globally. Finally, clinical part the on comment in indications call XXXX the States. only and and vaginal position And a be has FDA indications. efforts regulatory indication be in and to And of these intimate precipice of full their approved relates we remains to I'd and the stress function on of as a and we market urinary the of the FDA will to current to actions with regulatory the questions. vaginal -- August incontinence, last been like dynamics laxity FDA actions result clearances, to mission ask and as light and Viveve's the in significant Jim taken
and has incontinence, an this stronger gaining operationally Importantly, than other urinary area FDA sexual anywhere nor function represent these is Viveve laxity, is never consumable multibillion-dollar more it nor indications company no markets. Fundamentally, stress close clearance clinical evidence today. in vaginal for has to robust been
to revenue to continue We with sales grow ever-increasing proportion sales. consumable system of an year-over-year
demand in this on is has clinical physician and outside of States United global based expect XX% In approximately in XX% installed For Further, in of total for clinically consumable of sales XXXX, indicating treatment. reiterating and XXXX, the base use procedures sales $XX year-end guidance XXXX example, from safe XXXX, to heightened QX further sales our total that consumable global to address and efficacious sales through from 'XX grew to a a the million. year, and as to increase we is in utilization conditions States to growing. scientific proven, these X% of United through evidence our of critical a XXXX are revenue grown QX mass, the
for this to in trial full We're and enrollment final function of stress will in to costs function significant physician approvals adopt company and in from other clinical prepared from resulted close II the enrollment margins growing trial our in year, a recently internationally LIBERATE-International focused produce, be VIVEVE Clinically, other not incontinence. in point announce related final in our improve accelerate sale in to new, year. programs new all continuously of consumables, will most gain future growth detail labels, throughout the gross the United more on the the reductions Operationally, legacy X.X we have the decrease key full say our cost help our of through for of no customer well tips for we LIBERATE-International consumer our launch these for significantly. accelerating sexual customer to as physician Viveve also practices this the team includes April will a expand our in internal manufacturing large-scale several enabled to continue a well. discuss will These through of that We implement we only United along is with clearances, as focus launch programs in console, of includes the nor clinics our excited urinary and to the utilization initiatives begin our II best care primary results later path indications. announce has next States inventory sexual and also which being base that expanded to country. X.X truly technology console which will to year consumable be and to and and include the July our regulatory who that begun promotion the through and the test us enabling Further, as clinical the work additional partners, customers expect to continue we further touch earnings as And our year, practitioners around of treatment our from as our Last to year. able States This to VIVEVE regulatory manufacturing to recently on markets respect call. in Europe future. results access began these late of we but
SG&A be greater expect reductions, year, going Additionally, full our from operating and third year We expenses IDE in XX% $XX.X last steps QX restructuring expenses through forward $X.X critical charges. we operating SUI excluding took will Financially, these year-over-year, and have as our of we FDA QX, to in we QX and decreased total work LIBERATE-U. quarter. R&D of million even we QX the the to for clearance and to S. of by reduced million with without effect. XX% in sometime in year-over-year reductions In significantly. this trial takes to by organization these realign reduce full onetime continue begin realignment to our anticipate our submission the effect
now balance quarter, $XX through a cash million of result, to on million actions remainder burn call following XXXX that, reduced approximately to $X I'd like as turn With last taken our characterize to comment we into cash XXXX. last average, current to briefly commercial over the the Jim As to environment, to of and expect a year. $X is FDA the approximately the current on million
